Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5858)
All Articles published online
|
Publishing Process of This Article
|
Sep 7, 2014 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Bang KB, Kim HJ. Management of antiviral drug resistance in chronic hepatitis B. World J Gastroenterol 2014; 20(33): 11641-11649 [PMID: 25206270 DOI: 10.3748/wjg.v20.i33.11641] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i33/11641.htm |
| Number | Citing Articles |
| 1 |
Dominik Harms, Bo Wang, C. Patrick Papp, C.-Thomas Bock. Capturing virus evolution by proteomic bioinformatics: Hunting for characteristic mutations in the hepatitis E virus genome. Virulence 2018; 9(1): 13 doi: 10.1080/21505594.2017.1384526
|
| 2 |
Uma S. Singh, Varughese A. Mulamoottil, Chung K. Chu. 2′‐Fluoro‐6′‐methylene carbocyclic adenosine and its phosphoramidate prodrug: A novel anti‐HBV agent, active against drug‐resistant HBV mutants. Medicinal Research Reviews 2018; 38(3): 977 doi: 10.1002/med.21490
|
| 3 |
Jia Song, Xiaochao Zhang, Qianyun Ge, Chaoyi Yuan, Liang Chu, Hui‐fang Liang, Zhibin Liao, Qiumeng Liu, Zhanguo Zhang, Bixiang Zhang. CRISPR/Cas9‐mediated knockout of HBsAg inhibits proliferation and tumorigenicity of HBV‐positive hepatocellular carcinoma cells. Journal of Cellular Biochemistry 2018; 119(10): 8419 doi: 10.1002/jcb.27050
|
| 4 |
Yi-Jie Huang, Chi-Sen Chang, Yen-Chun Peng, Hong-Zen Yeh, Sheng-Shun Yang, Yury E. Khudyakov. On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B. PLOS ONE 2017; 12(3): e0174046 doi: 10.1371/journal.pone.0174046
|
| 5 |
Eva Maria Teegen, Max Magnus Maurer, Brigitta Globke, Johann Pratschke, Dennis Eurich. Liver transplantation for Hepatitis‐B‐associated liver disease ‐ Three decades of experience. Transplant Infectious Disease 2019; 21(1) doi: 10.1111/tid.12997
|
| 6 |
Hao Li, Chunyu Sheng, Shan Wang, Lang Yang, Yuan Liang, Yong Huang, Hongbo Liu, Peng Li, Chaojie Yang, Xiaoxia Yang, Leili Jia, Jing Xie, Ligui Wang, Rongzhang Hao, Xinying Du, Dongping Xu, Jianjun Zhou, Mingzhen Li, Yansong Sun, Yigang Tong, Qiao Li, Shaofu Qiu, Hongbin Song. Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9. Frontiers in Cellular and Infection Microbiology 2017; 7 doi: 10.3389/fcimb.2017.00091
|
| 7 |
Jeong Eun Song, Jun Yong Park. Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B. Expert Opinion on Pharmacotherapy 2021; 22(18): 2427 doi: 10.1080/14656566.2021.1967321
|
| 8 |
Sajad Najafi, Shing Cheng Tan, Shahin Aghamiri, Pourya Raee, Zahra Ebrahimi, Zahra Kargar Jahromi, Yazdan Rahmati, Javid Sadri Nahand, Ahmad Piroozmand, Vahid Jajarmi, Hamed Mirzaei. Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections. Biomedicine & Pharmacotherapy 2022; 148: 112743 doi: 10.1016/j.biopha.2022.112743
|
| 9 |
Kristen K. Irwin, Nicholas Renzette, Timothy F. Kowalik, Jeffrey D. Jensen. Antiviral drug resistance as an adaptive process. Virus Evolution 2016; 2(1): vew014 doi: 10.1093/ve/vew014
|
| 10 |
Xiaolin Li, Kai Zhou, Haiying He, Qiong Zhou, Ya Sun, Lijuan Hou, Liang Shen, Xiaofei Wang, Yuedong Zhou, Zhen Gong, Shibo He, Huangtao Jin, Zhengxian Gu, Shuyong Zhao, Long Zhang, Chunyan Sun, Shansong Zheng, Zhe Cheng, Yidong Zhu, Minghui Zhang, Jian Li, Shuhui Chen. Design, Synthesis, and Evaluation of Tetrahydropyrrolo[1,2-c]pyrimidines as Capsid Assembly Inhibitors for HBV Treatment. ACS Medicinal Chemistry Letters 2017; 8(9): 969 doi: 10.1021/acsmedchemlett.7b00288
|
| 11 |
Brígida Helena da Silva Meneghello, Márcia Maria Costa Nunes Soares, Vanessa Cristina Martins Silva, Marcilio Figueiredo Lemos, Murilo Castro Cervato, João Caetano Filho, Roberta Sitnik, Tânia Cristina Higino Estécio, Adriana Parise Compri, João Renato Rebello Pinho, Regina Célia Moreira. Hepatitis B in the Northwestern region of Sao Paulo State: genotypes and resistance mutations. Revista do Instituto de Medicina Tropical de São Paulo 2021; 63 doi: 10.1590/s1678-9946202163078
|
| 12 |
Lu Chen, Wen-Guang Liu, Fei Xiong, Chao Ma, Chen Sun, Yi-Ren Zhu, Xing-Guang Zhang, Zhong-Hua Wang. 3D-QSAR, molecular docking and molecular dynamics simulations analyses of a series of heteroaryldihydropyrimidine derivatives as hepatitis B virus capsid assembly inhibitors. New Journal of Chemistry 2021; 45(47): 22062 doi: 10.1039/D1NJ02542B
|
| 13 |
Zhuo-Lun Song, Yu-Jun Cui, Wei-Ping Zheng, Da-Hong Teng, Hong Zheng. Application of nucleoside analogues to liver transplant recipients with hepatitis B. World Journal of Gastroenterology 2015; 21(42): 12091-12100 doi: 10.3748/wjg.v21.i42.12091
|
| 14 |
Arjun Bagai, Arathi Kulkarni, Mayur S. Parmar. Encyclopedia of Toxicology. 2024; : 629 doi: 10.1016/B978-0-12-824315-2.01080-0
|
| 15 |
Gaëtan Ligat, Eloi R Verrier, Michael Nassal, Thomas F Baumert. Hepatitis B virus–host interactions and novel targets for viral cure. Current Opinion in Virology 2021; 49: 41 doi: 10.1016/j.coviro.2021.04.009
|
| 16 |
Ramalingam Peraman, Sathish Kumar Sure, V. N. Azger Dusthackeer, Naresh Babu Chilamakuru, Padmanabha Reddy Yiragamreddy, Chiranjeevi Pokuri, Vinay Kumar Kutagulla, Santhivardhan Chinni. Insights on recent approaches in drug discovery strategies and untapped drug targets against drug resistance. Future Journal of Pharmaceutical Sciences 2021; 7(1) doi: 10.1186/s43094-021-00196-5
|
| 17 |
Yuya Kato, Hirotaka Tabata, Kumiko Sato, Mariko Nakamura, Izumu Saito, Tomoko Nakanishi. Adenovirus Vectors Expressing Eight Multiplex Guide RNAs of CRISPR/Cas9 Efficiently Disrupted Diverse Hepatitis B Virus Gene Derived from Heterogeneous Patient. International Journal of Molecular Sciences 2021; 22(19): 10570 doi: 10.3390/ijms221910570
|
| 18 |
Shuhei Hige, Kouji Aoki, Daisuke Nakamoto, John F. Flaherty, Irina Botros, Hajime Mizutani, Akinobu Ishizaki, Hiroki Konishi, Jason Yuan, Masahisa Jinushi, Leslie J. Ng. Real‐world safety and effectiveness of tenofovir alafenamide for 144 weeks in Japanese patients with chronic hepatitis B. Journal of Viral Hepatitis 2024; 31(4): 165 doi: 10.1111/jvh.13912
|
| 19 |
Seth Kwabena Amponsah, Benjamin Tagoe. Viral Drug Delivery Systems. 2023; : 17 doi: 10.1007/978-3-031-20537-8_2
|